| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
EVREUX, France & MONTREAL—In mid-October, CiToxLAB, a contract research organization (CRO), announced the purchase of a new facility in the Laval area of Montreal to meet the growing demand for bioanalysis and biomarkers services in support of preclinical and clinical programs, offering shorter lead times for development programs.
 
The newly acquired Canadian facility is a turn-key, purpose-built laboratory described as “ultra modern” by CiToxLAB, and it is dedicated to small and large molecule bioanalysis by LC-MS/MS and ligand binding assays, flow cytometry, biomarkers, biodistribution by qPCR and immunology—that last category includes anti-drug antibody, neutralizing antibody, immunophenotyping and ELISPOT offerings. This expansion is an integral part of the strategic plan for CiToxLAB’s growth in global laboratory services.
 
“This expansion is the result of successful partnerships with our clients. It reinforces CiToxLAB’s commitment to enhancing the way we serve our customers. The relocation of some of our laboratory operations to this new building will free up areas in the main building, allowing us to increase our animal room capacity, resulting in shorter lead times for our clients,” said Jean-François Le Bigot, chairman and CEO of CiToxLAB Group. “The availability of this building, next door to our site in Laval, was an unexpected but excellent opportunity. I am very satisfied that our fast decision-making led CiToxLAB to acquiring this building in this ever-growing suburb of Montreal, where competition for this type of real estate is very high.”

Related Topics

Published In

Volume 13 - Issue 12 | December 2017

December 2017

December 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

An illustration of RNA strands

Decoding cell-free RNA to spot cancer early

Researchers are tapping into the potential of noncoding RNA in the blood to enhance cancer diagnostics. 
An illustration of three immune cells attacking a cancer cell, representing the mechanism of chimeric antigen receptor-based cell therapy

Cell therapy's next frontiers

As cell therapy evolves rapidly, what advancements are on the horizon? 
An illustration of a human heart on top of a DNA strand

Reversing rejection: gene therapy in modern transplantation

Emerging gene editing approaches pave the way for safer, more successful transplants.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue